Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Recruiting · NCT05289687 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell acute lymphoblastic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-09-15 | NCT05289687 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eastern Cooperative Oncology Group | 16 |
| Janssen, LP | 23 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Northwestern | Chicago | United States | 17 |